Claims for Patent: 9,808,445

Summary for Patent: 9,808,445

Title:	Factor IXa inhibitors
Abstract:	In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes. ##STR00001##
Inventor(s):	Sakurada; Isao (Gotemba, JP), Hirabayashi; Tomokazu (Gotemba, JP), Maeda; Yoshitaka (Gotemba, JP), Nagasue; Hiroshi (Gotemba, JP), Mizuno; Takashi (Gotemba, JP), Xu; Jiayi (Marlboro, NJ), Zhang; Ting (Princeton Junction, NJ), Smith; Cameron (Montgomery Village, MD), Parker; Dann (Cranford, NJ)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ) Mochida Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	15/303,322
Patent Claims:	1. A compound of the Formula (I): ##STR00148## or a pharmaceutically acceptable salt thereof; wherein: n is an integer of 0 or 1; p is an integer of 0 to 5; q is an integer of 0 to 4; r is an integer of 0 to 4; X is a nitrogen atom or CH; Y is an oxygen atom, a sulfur atom or NH (when n=0), Y is a nitrogen atom or CH (when n=1); Z.sup.1, Z.sup.2, Z.sup.3, and Z.sup.4 are each independently a nitrogen atom or CH; each R.sup.1 is a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxyl C.sub.1-6 alkyl group, a C.sub.3-12 cycloalkyl group, a C.sub.1-6 alkoxy group, a halogenated C.sub.1-6 alkoxy group, a C.sub.2-7 alkanoyl group, or a group of --NR.sup.AR.sup.B; R.sup.A and R.sup.B are each independently a hydrogen atom, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group or a C.sub.2-7 alkanoyl group; each R.sup.2 is independently a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a C.sub.3-12 cycloalkyl group, a C.sub.1-6 alkoxy group, or a halogenated C.sub.1-6 alkoxy group; each R.sup.3 is independently a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a C.sub.3-12 cycloalkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group, a cyanated C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy group, a C.sub.1-6 alkoxy C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkoxy group, a C.sub.2-7 alkanoyl group, a C.sub.1-6 alkylthio group, a C.sub.1-6 alkylsulfonyl group, or a group of --NR.sup.AR.sup.B, or oxo; a dotted line in a bicyclic substructure of Formula (I) represented by Formula (II): ##STR00149## represents a single bond when n is 0, or a double bond when n is 1; a substructure of ring A represented by Formula (III): ##STR00150## is a non aromatic heterocyclic group selected from: ##STR00151## is heteroaryl. 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein p is an integer of 0 to 1. 3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein q is an integer of 0 to 2. 4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein r is an integer of 0 to 2. 5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (V): ##STR00152## in Formula (I) is: ##STR00153## 6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein ##STR00154## is: ##STR00155## ##STR00156## wherein R.sup.4 is a hydrogen atom, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxyl C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy C.sub.1-6 alkyl group or a cyanated C.sub.1-6 alkyl group. 7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (II): ##STR00157## in Formula (I) is: ##STR00158## 8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (II): ##STR00159## in Formula (I) is: ##STR00160## 9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the substructure of Formula (III): ##STR00161## in Formula (I) is ##STR00162## 10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is a halogen atom, a cyano group, or a C.sub.1-6 alkyl group. 11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 is a halogen atom. 12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R.sup.3 is a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy group or oxo. 13. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein: R.sup.4 is a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group or a hydroxyl C.sub.1-6 alkyl group. 14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is N-((1S*,4S*,7R*)-2-(3-Aminobenzo[d]isoxazol-7-yl)-2-azabicyclo[2.2.1]hept- an-7-yl)-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Aminoisoxazolo[5,4-c]pyridin-7-yl)-2-azabicyclo[2.2- .1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylbenzo[d]isoxazol-7-yl)-2-azabicyclo[2- .2.1]heptan-7-yl)-2,6-dichloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide- ; N-((1S*,4S*,7R*)-2-(3-Amino-5-chlorobenzo[d]isoxazol-7-yl)-2-azabicyclo[- 2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chlorobenzo[d]isoxazol-7-yl)-2-azabicyclo[2- .2.1]heptan-7-yl)-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzam- ide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-a- zabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)be- nzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)- -2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1H-1,2,4-triazol-1-yl)benzami- de; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-az- abicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1H-1,2,4-triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(pyrimidin-5-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(2-methoxypyrimidin-5-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzam- ide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-a- zabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)be- nzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)- -2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(pyridazin-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-4-(4H-1,2,4-triazol-4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(4-(2-hydroxyethyl)-1H-imidazol-1-yl)b- enzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl- )-2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(4-(2-hydroxyethyl)-1H-1,2,3-- triazol-1-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-(difluoromethyl)-4H-1,2,4-triazol-4- -yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(2-cyanopyrimidin-5-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-y- l)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-(difluoromethyl)-6-oxo-1,6-dihydrop- yridin-3-yl)benzamide; 4-([1,2,4]Triazolo[4,3-a]pyridin-6-yl)-N-((1S*,4S*,7R*)-2-(3-amino-4-chlo- roisoxazolo[5,4-c]pyridin-7-yl)-2-azabicyclo[2.2.1]heptan-7-yl)-2-chlorobe- nzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)- -2-azabicyclo[2.2.1]heptan-7-yl)-4-(1H-benzo[d]imidazol-1-yl)-2-chlorobenz- amide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2- -azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1H-imidazo[4,5-b]pyridin-1-yl)b- enzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl- )-2-azabicyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-(2-hydroxyethyl)-6-oxo-1,6- -dihydropyridin-3-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-6-oxo-1,6-dihydropyridazin-3- -yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-cyanoisoxazolo[5,4-c]pyridin-7-yl)-2-azabic- yclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl- )benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(3-(trifluoromethyl)-4H-1,2,4-triazol-- 4-yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-5-methylisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-2-oxo-1,2-dihydropyrimidin-5- -yl)benzamide; N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-2-chloro-4-(1-methyl-5-oxo-1,5-dihydro-4H-1,2,4-t- riazol-4-yl)benzamide or N-((1S*,4S*,7R*)-2-(3-Amino-4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabi- cyclo[2.2.1]heptan-7-yl)-3-chloro-5-(3-methyl-1H-1,2,4-triazol-1-yl)picoli- namide. 15. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier. 16. A method of treating a thromboembolic disorder selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, thromboembolic disorders in the chambers of the heart, unstable angina, an acute coronary syndrome, atrial fibrillation, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 17. The method of claim 16, further comprising administering to said patient at least one anticoagulant agent which is a thrombin inhibitor, a thrombin receptor (PAR-1) antagonist, a factor VIIa inhibitor, factor VIIIa inhibitor, a factor IXa inhibitor, a factor Xa inhibitor, a factor XIa inhibitor, TAFI and fibrinogen inhibitors. 18. A pharmaceutical composition comprising: a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent which is (a) an anticoagulant, (b) an anti-thrombin agent, (c) an anti-platelet agent, (d) a fibrinolytic, (e) a hypolipidemic agent, (f) an antihypertensive agent, or (g) an anti-ischemic agent. 19. A pharmaceutical composition comprising: a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent which is (a-1) warfarin, (a-2) heparin, (a-3) aprotinin, (a-4) synthetic pentasaccharide, (a-5) direct acting thrombin inhibitors including hirudin and argatroban, (a-6) a factor VIIa inhibitor, (a-7) a factor VIIIa inhibitor, (a-8) a factor IXa inhibitor different from the compounds of Formula (I), (a-9) a factor Xa inhibitor, (a-10) a factor XIa inhibitor, (a-11) a thrombin inhibitor, (a-12) a TAFI, (a-13) a fibrinogen inhibitor, (b-1) a boroarginine derivative, (b-2) a boropeptide, (b-3) heparin, (b-4) hirudin, (b-5) argatroban, (c-1) a NSAID, (c-2) a IIb/IIIa antagonist, (c-3) a thromboxane-A2-receptor antagonist, (c-4) a thromboxane-A2-synthetase inhibitor, (c-5) a PDE-III inhibitor, (c-6) a PDE V inhibitor, (c-7) a ADP receptor antagonist, (c-8) an antagonist of the purinergic receptor P2Y1, (c-9) an antagonist of the purinergic receptor P2Y12, (d-1) tissue plasminogen activator (TPA, natural or recombinant) and modified forms thereof, (d-2) anistreplase, (d-3) urokinase, (d-4) streptokinase, (d-5) tenecteplase (TNK), (d-6) lanoteplase (nPA), (d-7) a factor VIIa inhibitor, (d-8) a PAI-I inhibitor, (d-9) an alpha-2-antiplasmin inhibitor, (d-10) an anisoylated plasminogen streptokinase activator complex, (e-1) a HMG-CoA reductase inhibitor, (e-2) a squalene synthetase inhibitor, (e-3) a fibrate, (e-4) a bile acid sequestrant, (e-5) an ACAT inhibitor, (e-6) a MTP inhibitor, (e-7) a lipooxygenase inhibitor, (e-8) a cholesterol absorption inhibitor, (e-9) a cholesterol ester transfer protein inhibitor, (f-1) an alpha adrenergic blocker, (f-2) a beta adrenergic blocker, (f-3) a calcium channel blocker, (f-4) a diuretics, (f-5) a renin inhibitor, (f-6) an angiotensin-converting enzyme inhibitor, (f-7) an angiotensin-II-receptor antagonist, (f-8) an ET receptor antagonist, (f-9) a Dual ET/All antagonist, (f-10) a neutral endopeptidase inhibitors, (f-11) a vasopepsidase inhibitor, (g-1) a Class I agent, (g-2) a Class II agent, (g-3) a Class III agent, a (g-4) Class IV agent, (g-5) a K+ cannel opener, (g-6) an IKur inhibitor or (g-7) a cardiac glycoside.

Details for Patent 9,808,445

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	12/29/1993		2034-04-16
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2034-04-16
Genentech, Inc.	TNKASE	tenecteplase	For Injection	103909	06/02/2000		2034-04-16